Supplementary Table 1 from Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors
Dalia Ercan(Dana-Farber Cancer Institute), Pasi A. Jänne(Harvard University), Joan Montero(United Biscuits (United Kingdom)), Marzia Capelletti(Caris Life Sciences (United States)), Takeshi Shimamura(University of Illinois Chicago), Kwok‐Kin Wong(NYU Langone Health), Calixte S. Monast(Broad Institute), Nathanael S. Gray(Stanford University), Anthony Letai(Dana-Farber Cancer Institute), Mohit Butaney(Brigham and Women's Hospital), Andrew H. Rogers(Roswell Park Comprehensive Cancer Center), Claire E. Repellin(Broad Institute), Madhavi Tadi(Memorial Sloan Kettering Cancer Center), Levi A. Garraway(Broad Institute), Eva M. Goetz(Broad Institute), Neal Rosen(Memorial Sloan Kettering Cancer Center), Elena V. Ivanova(Massachusetts General Hospital), Christine A. Pratilas(Johns Hopkins University), Matthew J. Lazzara(University of Virginia), Lynette M. Sholl(Brigham and Women's Hospital), Ophélia Maertens(American Institutes for Research), Chunxiao Xu(Tsinghua University), Masahiko Yanagita(Okayama University)
Cited by 0
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k